前蛋白转化酶枯草溶菌素9与心肌梗死之间关系的研究进展  

Research progress on the relationship between proprotein convertase subtilisin/kexin type 9 and myocardial infarction

作　　者：徐金 彭瑜[2,3] 张钲 XU Jin;PENG Yu;ZHANG Zheng(The First Clinical Medicine School of Lanzhou University,Lanzhou,Gansu 730000;The Heart Center of the First Hospital of Lanzhou University,Lanzhou,Gansu 730000;The Key Laboratory of Cardiovascular Diseases of Gansu Province,Lanzhou,Gansu 730000)

机构地区：[1]兰州大学第一临床医学院,甘肃省兰州市730000 [2]兰州大学第一医院心脏中心,甘肃省兰州市730000 [3]甘肃省心血管疾病重点实验室,甘肃省兰州市730000

出　　处：《中国动脉硬化杂志》2021年第11期1000-1006,共7页Chinese Journal of Arteriosclerosis

基　　金：甘肃省心血管疾病重点实验室建设项目(1206RTSA025);甘肃省心血管病临床医学研究中心(甘科技[2018]20号)。

摘　　要：前蛋白转化酶枯草溶菌素9(PCSK9)是一类前蛋白转化酶家族蛋白酶K亚家族成员,可以和低密度脂蛋白受体(LDLR)结合,阻抑了LDLR的重复利用,导致肝细胞表面LDLR减少,使外周血中低密度脂蛋白胆固醇(LDLC)水平增加,从而导致血脂代谢异常等一系列病理生理过程。目前研究表明PCSK9与心肌梗死存在一定的相关性,并可能通过独立于LDLC之外的途径调控心肌梗死的发生发展。本文就PCSK9与心肌梗死的相关研究进展进行综述。Proprotein convertase subtilisin/kexin type 9(PCSK9)is a member of the proteinase K subfamily of the proprotein convertase family,which can combine with low-density lipoprotein receptor(LDLR),and inhibit the repeated use of LDLR,resulting in a decrease in LDLR on the surface of liver cells,an increase in LDL levels in peripheral blood and a series of pathophysiological processes such as abnormal blood lipid metabolism.Current studies have shown that PCSK9 has a certain correlation with myocardial infarction,and may regulate the occurrence and development of myocardial infarction through a way independent of low-density lipoprotein cholesterol(LDLC).This article will review the research progress of PCSK9 and myocardial infarction.

关 键 词：前蛋白转化酶枯草溶菌素9 心肌梗死 基因多态性 血小板活化 

分 类 号：R5[医药卫生—内科学]